Eric Schmidt FCA
Stock Analyst at Cantor Fitzgerald
(4.86)
# 350
Out of 4,504 analysts
42
Total ratings
47.6%
Success rate
88.6%
Average return
Main Sectors:
Stocks Rated by Eric Schmidt FCA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Initiated Coverage: Buy | $206 | $199.15 | +3.44% | 4 | Jun 22, 2026 | |
| ODTX Odyssey Therapeutics | Initiated Coverage: Buy | n/a | $16.69 | - | 1 | Jun 2, 2026 | |
| LONA LeonaBio | Reiterated: Buy | n/a | $9.60 | - | 2 | Apr 7, 2026 | |
| GENB Generate Biomedicines | Initiated Coverage: Buy | n/a | $14.33 | - | 1 | Mar 24, 2026 | |
| SRRK Scholar Rock Holding | Maintained: Buy | n/a | $56.71 | - | 2 | Mar 19, 2026 | |
| LEGN Legend Biotech | Maintained: Buy | $75 → $74 | $27.08 | +173.26% | 4 | Dec 17, 2025 | |
| VSTM Verastem | Initiated Coverage: Buy | n/a | $5.53 | - | 1 | Oct 16, 2025 | |
| ALMS Alumis | Reiterated: Buy | n/a | $28.31 | - | 3 | Aug 14, 2025 | |
| BBIO BridgeBio Pharma | Initiated Coverage: Buy | n/a | $85.89 | - | 1 | Aug 13, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiated Coverage: Buy | n/a | $8.32 | - | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $15.25 | - | 8 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $39.71 | - | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $9.24 | n/a | 2 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.68 | n/a | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $41.23 | n/a | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $17.34 | n/a | 1 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.29 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $116.71 | n/a | 1 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $31.06 | n/a | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $31.95 | n/a | 1 | Nov 2, 2023 |
Biogen
Jun 22, 2026
Initiated Coverage: Buy
Price Target: $206
Current: $199.15
Upside: +3.44%
Odyssey Therapeutics
Jun 2, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $16.69
Upside: -
LeonaBio
Apr 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.60
Upside: -
Generate Biomedicines
Mar 24, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $14.33
Upside: -
Scholar Rock Holding
Mar 19, 2026
Maintained: Buy
Price Target: n/a
Current: $56.71
Upside: -
Legend Biotech
Dec 17, 2025
Maintained: Buy
Price Target: $75 → $74
Current: $27.08
Upside: +173.26%
Verastem
Oct 16, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $5.53
Upside: -
Alumis
Aug 14, 2025
Reiterated: Buy
Price Target: n/a
Current: $28.31
Upside: -
BridgeBio Pharma
Aug 13, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $85.89
Upside: -
BridgeBio Oncology Therapeutics
Aug 13, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $8.32
Upside: -
Jul 28, 2025
Reiterated: Buy
Price Target: n/a
Current: $15.25
Upside: -
Jul 25, 2025
Reiterated: Buy
Price Target: n/a
Current: $39.71
Upside: -
Jun 20, 2025
Reiterated: Hold
Price Target: n/a
Current: $9.24
Upside: n/a
Jun 2, 2025
Reiterated: Buy
Price Target: n/a
Current: $9.68
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $41.23
Upside: n/a
Mar 21, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $17.34
Upside: n/a
May 30, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $1.29
Upside: n/a
Apr 23, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $116.71
Upside: n/a
Apr 4, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $31.06
Upside: n/a
Nov 2, 2023
Initiated Coverage: Buy
Price Target: n/a
Current: $31.95
Upside: n/a